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Abstract
Background: Breast cancer belongs to the most frequent and severe cancer types in human.
Since excretion of modified nucleosides from increased RNA metabolism has been proposed as a
potential target in pathogenesis of breast cancer, the aim of the present study was to elucidate the
predictability of breast cancer by means of urinary excreted nucleosides.
Methods: We analyzed urine samples from 85 breast cancer women and respectivehealthy controls to
assess the metabolic profiles of nucleosides by a comprehensive bioinformatic approach. All included
nucleosides/ribosylatedmetaboliteswereisolatedbycis-diolspecificaffinitychromatographyandmeasured
with liquid chromatography ion trap mass spectrometry (LC-ITMS). A valid set of urinary metabolites was
selectedbyexclusionofallcandidateswithpoorlinearityand/orreproducibilityintheanalyticalsetting.The
bioinformatic tool of Oscillating Search Algorithm for Feature Selection (OSAF) was applied to iteratively
improve features for training of Support Vector Machines (SVM) to better predict breast cancer.
Results: After identification of 51 nucleosides/ribosylated metabolites in the urine of breast cancer
women and/or controls by LC- ITMS coupling, a valid set of 35 candidates was selected for subsequent
computational analyses. OSAF resulted in 44 pairwise ratios of metabolite features by iterative
optimization. Based onthis approach ultimately estimates for sensitivity and specificity of 83.5% and 90.6%
were obtained for best prediction of breast cancer. The classification performance was dominated by
metabolite pairs with SAH which highlights its importance for RNA methylation in cancer pathogenesis.
Conclusion: Extensive RNA-pathway analysis based on mass spectrometric analysis of
metabolites and subsequent bioinformatic feature selection allowed for the identification of
significant metabolic features related to breast cancer pathogenesis. The combination of mass
spectrometric analysis and subsequent SVM-based feature selection represents a promising tool for
the development of a non-invasive prediction system.
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Among all cancer diseases, breast cancer is worldwide the
most frequent cause of death for women between 30 and
60 years, responsible for approximately 500,000 casual-
ties per year in 2002 [1]. The treatment of cancer diseases
is inherently linked to early stage diagnosis. The
determination of tumor markers represents an integral
part of clinical therapy concepts. Unfortunately, the
established markers of breast cancer (e.g. CA-15-3 and
CEA) offer only unsatisfactory prediction accuracy and
therefore are not recommended for early diagnosis and
therapy surveillance [2].
New technological and biological developments have
the potential to increase the likelihood of discovering
new biomarker candidates. In the systems biology
context, novel targets have been identified on the
genome-, transcriptome- and proteome level. Recently,
the metabolome, representing the end products of
physiological processes, has experienced increasing
clinical attention.
Cell proliferation can also be controlled by metabolites
in a way similar to direct gene regulation. By triggering
concentration-dependent state changes in the expression
of transcription factors or induction of epigenetic
processes, metabolites are able to influence cancer
pathogenesis and therefore may play a critical role
during tumor progression.
Modified nucleosides, which are degradation products of
the cellular RNA metabolism, are suggested to be
important as possible tumor markers. In addition to
the primary constituents adenosine, guanosine, uridine
and cytidine, series of derived modified analogs are well
known. These modifications (e.g. methylation, sulfur/
oxygen-substitution, hypermodification) are posttran-
scriptionally implemented in the polynucleotide macro-
molecules and are considered to increase efficiency,
activity and integrity of RNA function [3]. Currently
more than 100 modified structures are known for
various RNA types [4].
During RNA turnover, hydrolytic enzymes catabolize
polynucleotides to the ribonucleoside level. The com-
mon ribonucleosides and corresponding nucleobases
can partly be recycled to rebuild intracellular RNA in the
salvage pathway. Due to the lack of specific phosphor-
ylases, modified nucleosides cannot enter this recycling
passage and therefore are excreted quantitatively as
biochemical end products [5]. Any disease or metabolic
imbalance affecting RNA turnover consequently results
in altered nucleoside excretion patterns, leading to the
hypothesis that RNA metabolites may be useful as
tumormarkers. Supporting this idea, significantly
increased amounts of modified nucleosides were found
in urine from patients suffering from breast carcinoma
[6], leukemia [7] and lung carcinoma [8].
In terms of analytics, the coupling of liquid-, gas- or
capillary liquid chromatography with mass spectro-
metric techniques like ESI-IT MS [9] and ESI tandem
MS [10] has been established as method of choice. In
addition, systems such as ESI-TOF MS [11], MALDI-TOF
MS [12] and especially FTICR MS [13] are valuable tools
for the elucidation of chemical structures.
The aim of our study was to classify patients with breast
cancer compared to healthy volunteers, based on LC-MS
analysis of urinary nucleosides using machine learning
techniques, which extract patterns from data and build
predictors. For instance principal component analysis
(PCA) is a commonly used method which was applied
by Yang et al. for classification of liver cancer patients by
means of HPLC-UV analysis. Based on a set of 15
nucleosides, 83% of the tumor patients were correctly
classified [14]. Artificial neural network (ANN) analysis
of urinary nucleosides was used by Seidel et al. to
distinguish between healthy controls and patients
suffering from various cancer diseases, yielding a
sensitivity of 97% and a specifity of 85% [15],
respectively.
Recently the support vector machine (SVM) became
increasingly popular due to its kernel approach and high
practical robustness. This technique has been applied in
various clinical research projects, analyzing tumor-
associated variances in the genomic profile [16], in
addition to protein expression [17] and metabolic [18]
patterns. Modified nucleosides have also been the target
for SVM approaches. For example Mao et al. [19] utilized
CE-MS measurements of RNA metabolites for classifica-
tion of bladder cancer patients (sensitivity 90%, specifity
100%), whilst previous work in our research group also
revealed the classification potential of modified nucleo-
sides (sensitivity 94%, specifity 86% [20] and sensitivity
88%, specifity 90% [21]).
Whereas clinical metabolomics often analyzes absolute
concentration values of a restricted set of metabolites
[15,19,21], the present work follows an extended
approach. According to the network characteristics in
metabolism, we additionally analyzed compounds from
pathways, interconnected to cellular RNA catabolism
such as histidine metabolism, purine biosynthesis and
methionine/polyamine cycle as well as from the nicoti-
nate/nicotinamide metabolism (Figure 1). Furthermore,
we used pairwise encoded metabolite ratios in order to
BMC Cancer 2009, 9:104 http://www.biomedcentral.com/1471-2407/9/104
Page 2 of 11
(page number not for citation purposes)assess tumor-associated shifts between substrates in the
metabolic flux.
Methods
Chemicals
Methanol LiChroSolv, hypergrade, purchased from
Merck/VWR (Darmstadt, Germany) was used for liquid
chromatography. Water was taken from an in-house
double distillation system. All other chemicals used were
of analytical grade.
Standard compounds available as reference for HPLC
separation and/or compound identification [13] were
dihydrouridine (DHU), pseudouridine (Ψ), cytidine
(C), pyridine, 3-hydroxypyridine, uridine (U), 3-methyl-
cytidine (m
3C), 1-ribosyl-4-carbamoyl-5-aminoimida-
zole (AICA riboside), 1-methyladenosine (m
1A),
7-methylguanosine (m
7G), inosine (I), 3-methyluridine
(m
3U), adenylosuccinic acid (phosphorylated analog of
N
6-succinyloadenosine), xanthosine (X), S-adenosylho-
mocysteine (SAH), 1-methylinosine (m
1I), 1-methylgua-
nosine (m
1G), N
4-acetylcytidine (ac
4C),
N
2-methylguanosine (m
2G), N
2,N
2,7-trimethylguano-
sine (m
2,2,7G), N
2,N
2-dimethylguanosine (m
2
2G),
N
6-threonylcarbamoyl-adenosine (t
6A), 5'-deoxy-5'-
methyl-thioadenosine (MTA).
All standards were from Sigma (Taufkirchen, Germany)
except m
2
2G, m
2,2,7Ga n dt
6A, obtained from Biolog
(Bremen, Germany), 1-methyl-L-histidine, purchased
from Calbiochem/Merck (Nottingham, UK) and pyri-
dine from Gruessing (Filsum, Germany). The internal
standard isoguanosine was kindly donated by Prof. J.H.
Kim of Seoul University, South Korea. Affigel boronate
was purchased from Biorad (Richmond, USA).
Urine samples
Spot urine samples were collected from 85 female
breast cancer patients (primarily in early tumor stage
T1) at the Department of Gynecology and Obstetrics,
University Hospital Tuebingen and from 85 female
healthy volunteers in a private clinical office (i.e.
women accompanying their children to the clinical
office). Tumor stage and age distributions are given in
figure 2 and 3. The clinical trial has been approved by
the local ethics committee of University Hospital
Tübingen. In order to minimize possible endo- and
exogenous perturbations on the urinary metabolite
pattern, we defined precise criteria for patient recruit-
ment. The samples were taken preoperatively and
neoadjuvant endocrine therapy, irradiation or che-
motherapy were not allowed. Patients taking immu-
nomodulating drugs, antibiotics, mistletoe
preparations, virustatics, allopurinol and dipyridamol
were not included in this study. Pregnancy, immune
mediated diseases, HIV, acute and chronic hepatitis,
chronic renal failure, acute infection of the urinary
tract as well as the patients' participation in a clinical
drug trial were defined as exclusion criteria. All
samples were stored at -80°C until extraction.
Figure 1
Some metabolite structures. Structures of some previously unknown urinary metabolites included in this study. M-4:
structure proposal based on combined FT MS and IT MS
n analysis. Others: identified in previous works [13].
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The metabolites were isolated from urine samples by cis-
diol specific affinity chromatography with 500 mg affigel
boronate per column (column dimensions: 150 × 15
mm). A volume of 1 mL urine was spiked with 50 μLo f
internal standard solution (0.1 mM isoguanosine in
water), mixed with 9 mL ammonium acetate solution
(0.25mM,pH8.8)andthenputonthecolumnfollowing
preconditioning with 45 mL ammonium acetate solution
(0.25 mM, pH 8.8). Because of the high backpressure
from the affigel boronate material, compressed air was
applied throughout the extraction procedure to maintain
a moderate flow rate at 3–4 mL/min. Ribosylated
compounds are bound reversibly and specifically at the
2',3'-cis-diol group. After washing with 10 mL ammo-
nium acetate solution (0.25 mM, pH 8.8) and 4 mL
ammonium acetate solution (0.25 mM, pH 8.8)/
methanol (9.5:0.5, v/v), elution was carried out with 6
mL methanol/water (2:8, v/v) and 50 mL 0.2 M formic
acid in methanol/water (1:1, v/v). The column was
reconditioned with 25 mL methanol/water (2:8, v/v)
and 45 mL ammonium acetate solution (0.25 mM,
pH 8.8) for the next sample. After each second extraction,
a blank sample (10 mL ammonium acetate solution
(0.25 mM, pH 8.8)) was analogously proceeded to
removeimpuritiesfromthecolumnandtoavoidpossible
c a r r y - o v e re f f e c t s .T h es o l v e n tf r o mt h es a m p l ee l u a t ew a s
removed using a rotary evaporator and the residuum was
dissolved again in 0.5 mL ammonium formate solution
(5 mM, pH 5). A volume of 10 μL was injected into the
HPLC-MS system.
LC-ESI-IT MS
The chromatographic separation of the urinary metabo-
lites was performed on an Agilent 1100 Series HPLC
system (Agilent, Waldbronn, Germany) consisting of a
Solvent Degasser (G 1379 A), a binary capillary pump (G
1389), an autosampler (G 1313 A), a column oven
operated at 25°C (G 1316 A) and a DAD (G 1315 B). The
chromatographic system consisted of a Merck LiChro-
CART Superspher 100 RP-18 endcapped column (125 ×
2.0 mm i.d., 4 μm (Merck, Darmstadt, Germany)) and a
solvent system of 5 mM ammonium formate buffer, pH
5.0, and methanol-water (3:2, v:v + 0.1% formic acid) at a
flow rate of 125 μL/min [9]. The LC-system was coupled
to an Esquire HCT-Ion trap mass spectrometer (Bruker
Daltonics, Bremen, Germany), equipped with an ESI
source and operated in positive ion detection mode.
The capillary voltage was set to 4 kV, the drying gas
temperature in the electrospray source was set to 350°C,
the nebulizer gas was set to 45 psi and the drying gas to
9.0 L/min. The data were acquired in standard enhanced
scanmode(8,100m/zpersecond)overamassrangeofm/
z200–600viaBrukerEsquireControlversion5.1.Forpost
processing, Bruker DataAnalysis version 3.1 was used.
Integration procedure
Semiquantitative concentration values were obtained via
integration of Extracted Ion Chromatograms (EIC). Due to
significantalkali affinity of certainanalyzedmetabolites, we
generallysummarizethecorresponding[MH]
+,[M N a]
+and
[MK]
+traces.TheEICswereprocessedwithaGaussfunction
smoothing algorithm contained in the DataAnalysis soft-
ware. For analytical and physiological normalization, the
integrated peak areas were related to the internal standard
and the urinary creatinine level (in mg/dl):
W
AreaAnalyte MH MNa MK
AreaIStd MH MNa M
=
++ ++ +
++ ++
( [ ][ ][ ] )
(( [ ] [ ] [ K K creatinine mg dl ]) [ / ] ) + ×
(1)
Figure 3
Age distribution. Histogram of the age distributions for
cancer and control patients.
Figure 2
Tumor stage distribution. Histogram of the tumor stage
distribution. The major fraction of patients had breast cancer
in the T1 stadium. The remaining patients were mostly T2
with the exception of 11.7% that divide up into the T3 and
the Tis stadium.
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For bioinformatic feature selection we encoded pairwise
combinations of semiquantitative concentrations of the
35 included metabolites (x, y). This resulted in 35 × 34 =
1190 encodings per sample. We used the encoding
function
exy
x
y
(,) a r c t a n =
⎛
⎝
⎜
⎞
⎠
⎟ (2)
and defined the case
ex xx
y y ( , ) arctan lim 0
0 2 0 = () = () = →
p ,w h e ny =0w a s
not detected.
Two problems are solved using this encoding, which
should be considered as a normalization step. Firstly, a
c o n s i s t e n tv a l u ef o rt h ec a s ew h e r eav a l u ew a sb e l o wt h e
detection threshold is obtained, and secondly, this
encodingmapse(x, y)ande(y,x)ontodifferentcodomain
ranges conserving argument order information. For more
information [see Additional file 1, 2 and 3].
Next, we applied Linear Discriminant Analysis (LDA)
[22] to visualize our encoding. As in the case of Principal
Component Analysis (PCA) a linear model is used to
visualize the data. In contrast to PCA the aim of LDA is
to find a linear model that maximally separates the
classes on a straight line.
To compare the encodings, we computed the LDA
projections to visualize the data set with and without
arctan-encoding (see figure 4). Because of the risk of
overfitting using more than 1190 features,
nonparametric feature selection is needed to reduce the
number of features used for prediction.
Therefore we used the Oscillating Search Algorithm for
Feature Selection (OSAF) [23] in combination with a
SVM to select a reduced set of optimized features for
classification. The OSAF wrapper method applies an
efficient strategy to select combinations from the power
set of features and uses the SVM as a black box to assess
the information content [24].
Our implementation operates in up- and down-swing
p h a s e sw h i c ha r eb a s e do nS e q u e n t i a lF o r w a r dS e l e c t i o n
(SFS) and Sequential Backward Selection (SBS). The SFS
greedily includes the feature, which maximally improves
the prediction error, while SBS removes the feature
which minimally reduces the error.
Having selected a feature set, the algorithm uses the SVM
to train a predictor for estimation of the generalization
performance. We evaluated the 10-fold cross validated
(CV) Matthews Correlation Coefficient (MCC) as
measure.
Given the true positives (TP), the true negatives (TN), the
false positives (FP) and the false negatives (FN), the
MCC is computed as
MCC
TP TN FP FN
=
⋅− ⋅
+ () + () + () + () TP FP TP FN TN FP TN FN
. (3)
This results in a value between +1.0 for perfect
predictions and -1.0 for maximal false predictions.
Furthermore, we computed the Leave-one-out (LOO)
estimate, which is an almost unbiased estimate for the
true generalization error [25].
During each evaluation of a feature set, the SVM model
parameters were chosen by grid search. We used a
modified implementation of LibSVM [26] that reports
all statistics needed for the computation of the MCC,
together with an OSAF wrapper written in Perl. The LDA
analysis was performed in R and the mutual information
below was computed using Matlab.
To remove redundancy in the list of features, we classified
the selected features into tumor and non-tumor relevant
according to current literature knowledge. Then we
a p p l i e dS B St or e m o v ea l lf e a t u r e sw h i c hh a dn oi m p a c t
on the MCC and where not tumor relevant.
To visualize the importance of each selected feature, we
computed the mutual information [22], defined as
Figure 4
LDA analysis. Projection of the class distribution onto a
straight line by Linear Discriminant Analysis for the discrete
and the arctan-encoded metabolite ratios. As can be seen,
the pairwise-encoding offers a better partitioning of cancer
and healthy collectives by a linear model than the sole
concentration features.
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(,)
()()
.
(,) ( ) ()
=
∈× ∫ (4)
This value represents a quantity which measures the
mutual dependence between two variables (here class
label and metabolite encodings). Although prediction
performance is obtained from a complex set of variables,
even those variables with small information content may
be essential in combination with others (see [24]).
Results
Generating a valid metabolic profile
B a s e do nas e to f5 1d e t e c t a b l eu r i n a r yc i s - d i o l
metabolites in the applied sample volume of 1 mL
urine, we first attempted to define a valid metabolic
profile. To this end, two main criteria were established
for the inclusion of compounds. First, the respective
metabolite should meet the analytical criteria of linearity
and reproducibility. Second, the biochemical origin of
the compound should constitute a possible tumor-
associated background.
In this manner, 16 compounds were excluded due to
poor linearity/reproducibility and/or missing pathophy-
siological relevance. In the latter case, we eliminated
potential secondary metabolites from endosymbiontic
bacteria, metabolites influenced by nutrition [13] and
compounds originated or influenced in sample prepara-
tion. The resulting metabolic profile for SVM training is
shown in Table 1.
Proof of reproducibility
For proof of reproducibility, 10 mL of a spot urine
sample were spiked with 500 μL internal standard
(0.1 mM isoguanosine in water). The obtained solution
Table 1: Included metabolites
No. [MH
+]R T M e t a b o l i t e R
2 RSD [%] Symbol Metabolic pathway
#
1 302 3.0 1-ribosyl-3-methyl-5-(2-aminocarboxyethyl)-imidazolium 0.9875 7.4 M-1 (H)
2 247 4.3 Dihydrouridine 0.9855 6.0 DHU R
3 245 4.5 Pseudouridine 0.9889 3.3 Ψ R
4 212 5.0 1-ribosyl-pyridinium 0.9771 5.7 M-2 (N)
5 244 6.5 Cytidine 0.9815 12.0 C R
6 346 7.0 3-(3-aminocarboxypropyl)-uridine 0.9957 3.5 acp
3U R
7 302 7.0 5-carbamoylmethyluridine 0.9977 4.0 ncm
5U R
8 228 7.5 1-ribosyl-3-hydroxy-pyridinium 0.9932 2.1 M-3 (N)
9 245 8.5 Uridine 0.9981 8.4 U R
10 258 9.5 3-methylcytidine 0.9787 2.7 m
3C R
11 259 10.5 1-ribosyl-4-carbamoyl-5-amino-imidazole 0.9942 6.0 AICA riboside N
12 282 12.0 1-methyladenosine 0.9949 3.1 m
1A R
13 271 14.0 1-ribosyl-5-carbamoyl-2-oxo-pyridine 0.9903 3.7 2,5-PCNR N
14 298 17.5 7-methylguanosine 0.9727 10.2 m
7G R
15 269 18.0 Inosine 0.9911 3.0 I R
16 271 20.5 1-ribosyl-3-carbamoyl-4-oxo-pyridine 0.9955 2.1 3,4-PCNR N
17 296 21.5 1, N
6-dimethyladenosine 0.9959 2.9 m
6
1A R
18 259 23.5 3-methyluridine 0.9972 3.0 m
3U R
19 384 24.5 N
6-succinyloadenosine 0.9568 11.3 N
6-SAR P
20 285 25.0 Xanthosine 0.9974 4.0 X R
21 385 27.5 S-adenosylhomocysteine 0.9926 4.4 SAH MP
22 283 29.0 1-methylinosine 0.9969 3.8 m
1I R
23 298 31.0 1-methylguanosine 0.9920 4.5 m
1G R
24 293 32.0 ? 0.9918 14.9 293 ?
25 286 32.5 N
4-acetylcytidine 0.9934 7.6 ac
4C R
26 298 33.5 2-methylguanosine 0.9979 8.2 m
2G R
27 376 34.5 9-ribosyl-6-taurinopurine 0.9974 6.2 M-4 (R)
28 398 40.0 2-methylthio-N
6-(cis-hydroxyisopentenyl)-adenosine 0.9983 4.5 ms
2io
6A R
29 326 41.0 N
2,N
2,7-trimethylguanosine 0.9911 2.7 m
2,2,7G R
30 312 41.5 N
2,N
2-dimethylguanosine 0.9925 4.7 m
2
2G R
31 333 42.5 5-methoxycarbonylmethyl-2-thiouridine 0.9981 4.6 mcm
5s
2U R
32 413 46.5 N
6-threonylcarbamoyladenosine 0.9963 3.5 t
6A R
33 298 48.0 5'-deoxy-5'-methyl-thioadenosine 0.9987 13.3 MTA MP
34 427 49.5 N
6-methyl-N
6-threonylcarbamoyladenosine 0.9920 5.5 m
6t
6A R
35 459 50.0 2-methylthio-N
6-threonylcarbamoyladenosine 0.9887 3.9 ms
2t
6A R
Set of included ribosylated metabolites for bioinformatic data evaluation.
# R: RNA metabolism, H: histidine metabolism, N: nicotinate/nicotinamide metabolism,
MP: methionine/polyamin cycle, P: purine biosynthesis, ?: unknown. Abbreviations in parenthesis: pathway proposal, RT: retention time. (Structures
M - 1t oM - 4s e eF i g u r e1 . )
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mixed with 9 mL ammonium acetate solution (0.25 mM,
pH 8.8) to give a sample volume of 10 mL, vortexed and
proceeded as described in sections "extraction proce-
dure" and "integration procedure". The obtained values
for reproducibility are shown in Table 1. A compound
was considered to be reproducible for RSD values ≤ 15%.
Proof of linearity
For proof of linearity, two different spot urine samples
were separated in specimens of 0.25 mL, 0.5 mL, 1 mL,
2m La n d4m L .E a c hs a m p l ew a ss p i k e dw i t h5 0μL
internal standard and mixed with 9 mL ammonium
acetate solution (0.25 mM, pH 8.8) to give a sample
volume of 10 mL. The obtained solutions were pro-
ceeded as described. The obtained values are shown in
Table 1. Linearity was considered for regression coeffi-
cients ≥ 0.95.
Feature selection with best classification performance
As can be seen in figure 4 both collectives (cancer/healthy)
are clearly separable using the arctan-encoding, while the
usage of the semiquantiative concentrations yields a poor
separation performance. Therefore a learning algorithm can
construct better separating models on the transformed data
usingthearctan-encodingthanontherawfeatureencoding.
The application of the OSAF yielded a set of 59 feature
combinations with best classification performance. The
successive pruning step with SBS left a set of 44 mainly
pathophysiological relevant feature combinations, without
degrading classification performance (Table 2). Final perfor-
mance was a sensitivity of 83.5% and a specifity of 90.6%
withap-value<<0.05(Two-sidedFisher'sexacttest,Table3)
for 10-fold cross validation. The leave-one-out validation
yielded83.5%sensitivityandaspecifityof85.9%alsohaving
p-value << 0.05. Figure 5 shows the mutual information of
the selected combination. In comparison to prior work [20]
the mutual information identifies more informative features
that are obtained by using a pairwise-encoding.
Discussion
The obtained feature selection reflects characteristic, tumor-
associated shifts in the analyzed metabolite patterns.
Table 2: Selected feature set
No. encoding* metabolite ratio No. encoding metabolite ratio
1 arctan (1/7)* M-1/ncm
5U 23 arctan (20/3) X/ψ
2 arctan (1/12) M-1/m
1A 24 arctan (20/35) X/ms
2t
6A
3 arctan (2/21) DHU/SAH 25 arctan (21/30) SAH/m
2
2G
4 arctan (3/18) Ψ/m
3U 26 arctan (22/30) m
1I/m
2
2G
5 arctan (5/7) C/ncm
5U 27 arctan (23/18) m
1G/m
3U
6 arctan (5/11) C/AICA riboside 28 arctan (25/5) ac
4C/C
7 arctan (6/18) acp
3U/m
3U 29 arctan (25/10) ac
4C/m
3C
8 arctan (6/19) acp
3U/N
6-SAR 30 arctan (25/22) ac
4C/m
1I
9 arctan (8/23) M-3/m
1G 31 arctan (26/28) m
2G/ms
2io
6A
10 arctan (9/21) U/SAH 32 arctan (26/30) m
2G/m
2
2G
11 arctan (11/5) AICA riboside/C 33 arctan (27/13) M-4/2,5-PCNR
12 arctan (11/33) AICA riboside/MTA 34 arctan (28/19) ms
2io
6A/N
6-SAR
13 arctan (12/10) m
1A/m
3C 35 arctan (29/34) m
2,2,7G/m
6t
6A
14 arctan (12/18) m
1A/m
3U 36 arctan (29/35) m
2,2,7G/ms
2t
6A
15 arctan (13/9) 2,5-PCNR/U 37 arctan (30/21) m
2
2G/SAH
16 arctan (13/20) 2,5-PCNR/X 38 arctan (31/2) mcm
5s
2U/DHU
17 arctan (14/21) m
7G/SAH 39 arctan (31/24) mcm
5s
2U/293
18 arctan (14/26) m
7G/m
2G 40 arctan (33/11) MTA/AICA riboside
19 arctan (16/22) 3,4-PCNR/m
1I 41 arctan (33/17) MTA/m
6
1A
20 arctan (18/10) m
3U/m
3C 42 arctan (33/34) MTA/m
6t
6A
21 arctan (18/21) m
3U/SAH 43 arctan (34/12) m
6t
6A/m
1A
22 arctan (19/30) N
6-SAR/m
2
2G 44 arctan (34/19) m
6t
6A/N
6-SAR
Feature set for best classification performance.
*Numbering of arctan encoding combinations consistent with table 1. For metabolite abbreviations, please refer to Table 1.
Table 3: Generalization performance
Validation Sensitivity [%] Specifity [%] MCC* TP FN TN FP p-value
CV (10 fold) 83.5 90.6 0.743 71 14 77 8 2.2 × 10
-16
LOO 83.5 85.9 0.694 71 14 73 12 2.2 × 10
-16
Prediction results for the best obtained feature selection. The p-value was computed by the Fishers' Exact Test.
* for abbreviations refer to main text.
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(page number not for citation purposes)The action of methyltransferases plays a key role in the
aberrant RNA metabolism in tumor genesis [27]. In this
context, the selected feature combinations of methylated
nucleosides No. 13 (m
1A/m
3C), 15 (m
1A/m
3U), 20 (m
3U/
m
3C), 26(m
1I/m
2
2G),27(m
1G/m
3U),35(m
2,2,7G/m
6t
6A)
and 36 (m
2,2,7G/ms
2t
6A) show pathophysiologically moti-
vated pattern shifts. Tsutsui et al. already reported on
significant alterations in the ratios of the monophosphory-
lated, methylated nucleosides m
6A, m
5C, m
2G and m
2
2G
from tRNA in normal hepatocytes and Novikoff-Hepatoma
cells [28]. Changes in the enzyme specifity, resulting in an
enlarged set of possible modification sites in the poly-
nucleotide molecule, were postulated as biochemical back-
ground. Analogous alterations in the methylation capacity
have also been reported in breast cancer [29]. The observed
shifts in the excretion ratios of certain methylated nucleo-
sides can be generally traced back to this phenomenon.
A metabolic pathway with considerable classification
potential was found to be the methionine-/polyamine
cycle. Striking analogies have been found to our previous
projects, dealing with metabolic profiling in cell culture
supernatants of breast cancer cell line MCF-7. In this work,
characteristic tumor-associated alterations in the methio-
nine/polyamine cycle had been observed for the excretion
behaviorofthecorrespondingdegradationproducts[30].In
particular, these were metabolites from the ubiquitous
enzymatic co-substrate SAM. Figure 6 shows a connectivity
map of the corresponding biochemical pathways.
The ribosyl-conjugated methionine scaffold of SAM
provides functional groups for various enzymatic
reactions. The biosynthesis of the modified uridine
derivative proceeds via selective transfer of the carbox-
yaminopropyl moiety on uridine positions in the RNA
molecule [31]. In this context, the feature combination
10 (U/SAH) is of great importance. The high information
content in the classification process is probably based on
alterations in the competing reaction pathways SAM Æ
SAH and SAM Æ U Æ acp
3U. In cancer diseases, the
elevated cellular methylation capacities lead to higher
synthesis and thus excretion of SAH, consequently
resulting in altered SAH/U ratios. This presumption is
supported by the fact that ratio No. 3 (DHU/SAH) is also
differing between breast cancer patients and healthy
control subjects. DHU is a uridine derivative, modified
through enzymatic reduction of uridine.
The most characteristic indication for tumor-associated
alterations in the reaction of SAM-induced carboxyami-
nopropyltransfer and SAM-induced methyltransfer is
reflected by feature combination 7 (acp
3U/m
3U). Both
modified nucleosides represent the primary metabolites
of uridine in the mentioned reaction pathways and
contribute to the resulting classification performance of
the SVM.
Distinctive metabolite ratios within the sets of modified
uridines such as No. 4 (Ψ/m
3U) and No. 38 (mcm
5s
2U/
DHU), adenosines (No. 43, m
6t
6A/m
1A) and cytidines
(No. 29, ac
4C/m
3C) were selected in the course of the
performed feature selection due to their high informa-
tion content. Alterations in the concentration ratios
within one nucleoside group can be attributed to tumor-
associated changes in expression and activities of the
involved modifying enzyme systems.
The deregulation of SAM-induced methyltransfer reac-
tions in tumor genesis is reflected by three additional
feature combinations No. 17 (m
7G/SAH), 21 (m
3U/
SAH) and 37 (m
2
2G/SAH). The methylated nucleosides
m
7G, m
3Ua n dm
2
2G are posttranscriptionally
Figure 5
Mutual Information Content. This figure shows the
mutual information content of the selected metabolite ratios.
On the x-coordinate all pairwise encoded features are listed
with their indexes in table 2 in brackets.
Figure 6
Connectivity map. Connectivity map of SAM and related
metabolites.
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(page number not for citation purposes)synthesized via transfer of the activated SAM methyl
function on defined positions in the polynucleotide
molecules. The SAM cosubstrate involved is converted to
SAH. As a consequence, the elevated methylation
capacities in tumor cells result in higher levels of
methylated nucleosides and thus an increased degrada-
tion of SAM yielding SAH. The latter is known as a
potent inhibitor of methyltransferases [32]. An elevated
level of excretion has already been observed in our
studies on metabolite excreti o ni nc e l lc u l t u r es u p e r -
natants of tumor cell line MCF-7 compared to breast
epithelial cell line MCF-10A [30]. As a main conclusion,
tumor cells most likely avoid the aforementioned
inhibitory effects by active excretion of surplus SAH,
resulting in ratio shifts to methylated nucleosides.
In this context, the feature combinations No. 41 (MTA/
m
6
1A) and 42 (MTA/m
6t
6A) should also be mentioned.
MTA is the primary degradation product of SAM in case
of transfer reactions of the aminocarboxypropyl moiety
on uridines in the RNA macromolecules. Furthermore it
is built by transfer of propylamino groups on the
polyamine compounds putrescine and spermidine via
the decarboxylated byproduct of SAM, dcSAM. Poly-
amines are known to be involved in important cell
growth and development processes, which thereby also
have great impact in tumor genesis [33]. The tumor-
associated, deregulated influence on the metabolic flow
of the methionine/polyamine cycle probably leads to an
accumulation of MTA. Due to its well-known inhibitory
effects on methyltransfer reactions, a simultaneous
elevated excretion might take place in tumor genesis
[30]. Due to the contrarily proceeding SAM-induced
methyltransfer reactions leading to m
6
1Aa n dm
6t
6A,
shifts in the metabolite ratios involving MTA were
observed.
Another interesting metabolite ratio is No. 28, featuring
cytidine and its acetylated derivative ac
4C. The latter is
built in rRNA and tRNA by means of an acetyltransferase
system and most probably acetyl-CoA as donor of the
acetyl function [4].
In eukaryotic tRNA, ac
4C is exclusively implemented on
position 12 in the D-loop. The exact biological function
is still unknown. A general stabilization of the tRNA
structure has been discussed in [34]. Elevated amounts
of acetylated cytidine have been described in numerous
reports, dealing with the altered excretion of modified
nucleosides in cancer diseases [35]. The selection of the
C/ac
4C combination in our classification approach
appears in analogy to the results of our previous work
with cell culture supernatants, which showed distinctive
alterations in the excretion of cytidine in breast cancer
cells [30].
Selection of feature combination No. 32 also reflects
relevant attributes of tumor-associated alterations of
RNA metabolism. The monomethylated guanosine
derivative m
2G and its dimethylated analogon m
2
2G
derive from eukaryotic tRNA and rRNA [4] and have
both been postulated as potential tumor markers [36].
During biosynthesis of the methylated guanosines, the
precursor molecule m
2Gi sc o n v e r t e dt om
2
2Gv i at h e
tRNA-N
2,N
2-dimethyltransferase [37]. In tumors of liver
and kidney, a distinctively elevated activity of the
involved enzyme system has been observed by Craddock
[38]. The resulting elevated biosynthesis of m
2
2G
explains the observed tumor-associated shifts in the
m
2G/m
2
2Gr a t i o .
Conclusion
In conclusion, we found a reasonable set of 44 tumor-
related metabolite pairs measured by LC-IT MS with a
SVM prediction performance of 83.5% sensitivity and
90.6% specifity (p-value << 0.05). We demonstrate that
semiquantitative measurements are valuable for pattern
detection using nonparametric machine learning algo-
rithms. Our results constitute the basis for the develop-
ment of a noninvasive and efficient screening method.
Although we have analyzed a balanced dataset of 170
urine samples and estimated the prediction performance
using the nearly unbiased LOO, a validation study
remains future work. It is essential to perform a large-
scale and multi-centric evaluation study of the method
to prove it as valid for clinical testing.
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